May 28 (Reuters) - Veru Inc VERU.O:
VERU REPORTS POSITIVE SAFETY RESULTS FROM PHASE 2B QUALITY STUDY: ENOBOSARM ADDED TO SEMAGLUTIDE LED TO GREATER FAT LOSS, PRESERVATION OF MUSCLE, AND FEWER GASTROINTESTINAL SIDE EFFECTS COMPARED TO SEMAGLUTIDE ALONE
VERU INC - TOPLINE DATA FOR PHASE 2B EXTENSION STUDY EXPECTED IN SECOND QUARTER
VERU INC: TRIAL MET ITS PRESPECIFIED PRIMARY ENDPOINT
VERU INC - REQUESTS END OF PHASE 2 MEETING WITH FDA FOR PHASE 3 REGULATORY CLARITY
Source text: ID:nGNX3V5L3M
Further company coverage: VERU.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.